Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ:AFFX) today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories ...

Munich, Regensburg (Germany) Feb.17, 2006: KFB - Center of Excellence for Fluorescent Bioanalysis, an authorized Affymetrix Service Provider, and Genomatix Software GmbH signed a cooperation and ...

ExonHit Therapeutics has announced a supply and service provider agreement to combine Affymetrix' GeneChip® microarray platform and ExonHit's alternative RNA splicing technologies and expertise.

Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...

The DNA marketplace is changing: the technology is maturing, whole human genome arrays, as well as those of model organisms, are beginning to make it onto the market, and researchers have more choices ...

BOSTON--(BUSINESS WIRE)--April 4, 2006--Labs can automate sample processing requests and results file management using Stone Bond's EE-LIMS system Stone Bond Technologies, a leading provider of ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered into a definitive agreement to acquire Panomics Inc., a privately held Fremont, Calif.-based ...

Mindy Lee-Olsen, 408-731-5523 (Media)Vice President, Marketing ServicesorDoug Farrell, 408-731-5285 (Investors)Vice President, Investor Relations (NASDAQ:AFFX) announced today the availability of ...

Recombinant human erythropoietin (rEpo) is neuroprotective in neonatal models of brain injury. Proposed mechanisms of neuroprotection include activation of gene pathways that decrease oxidative injury ...